Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease - Summary - MDSpire

Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease

At ARVO 2026, Ikarovec presented 4 posters showcasing its bicistronic platform that combines neuroprotection and complement modulation.

  • By

  • Katie Binley, PhD

  • May 1, 2026

  • 3 min

Share

Objective:

To develop dual-pathway gene therapies for retinal degenerative diseases, specifically targeting geographic atrophy (GA).

Key Findings:
  • Current single-pathway therapies for GA show modest effects and inconsistent improvements in visual function.
  • GA is multifactorial, necessitating simultaneous targeting of multiple pathways.
  • Neuroprotection is critical for achieving meaningful functional outcomes in GA treatment.
Interpretation:

The dual-pathway approach may overcome limitations of existing therapies by providing both anatomical and functional benefits.

Limitations:
  • The study does not provide extensive clinical trial data for IKAR-001.
  • Further research is needed to validate the long-term efficacy of the bicistronic platform.
Conclusion:

Ikarovec's gene therapy represents a promising next-generation treatment for GA and potentially other retinal diseases.

Original Source(s)

Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease

  • by Katie Binley, PhD

  • May 1, 2026

Related Content

Drs. Berrocal Reflect on ASRS 2026

ASRS 2026 meeting program chair Audina M. “Nina” Berrocal, MD, FASRS, joins Maria H. Berrocal, MD, to discuss the meeting’s highlights, surgical sessions, and educational approach.

Malpositioned orbital implants: indications for implant removal and secondary reconstructive techniques

A First Look at Phase 2 ArMaDa Data

Arshad M. Khanani, MD, FASRS, discusses phase 2 findings for OCU410, an investigational gene therapy for geographic atrophy. A phase 3 program is expected to begin later this year.